ONCY Q1 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Cash Position: As of March 31, 2025, Oncolytics reported cash and cash equivalents of $15.3 million, providing runway through key milestones into Q3 2025.
Operating Expenses: Net cash used in operating activities was $6.5 million, down from $7.5 million in Q1 2024, reflecting lower expenditures.
R&D Expenses: Totaled $4.1 million, a decrease from $5.7 million in Q1 2024, primarily due to reduced clinical trial costs.
Net Loss: Reported at $6.7 million or $0.08 per share, slightly improved from $6.9 million or $0.09 per share in the prior year.
Capital Access: Announced a $20 million share purchase agreement with Alumni Capital, providing flexible capital access.

2. Strategic Updates and Business Highlights

CEO Search: An active search for a new CEO is underway, aimed at finding a leader focused on clinical trial execution for pelareorep (pela).
Clinical Progress: Positive interim results from GOBLET Cohort 4 showed a 33% objective response rate in anal carcinoma. Cohort 5 is currently enrolling patients with metastatic pancreatic cancer, funded by a $5 million grant from PanCAN.
Breast Cancer Studies: Two Phase 2 studies (IND-213 and BRACELET-1) demonstrated significant survival benefits for pela in HR-positive/HER2-negative breast cancer, supporting its potential for regulatory approval.
Business Development: Engaging with potential partners at industry conferences to maximize the value of pela across multiple indications.

3. Forward Guidance and Outlook

Clinical Data Sharing: Initial efficacy data from GOBLET Cohort 5 is expected later this year, with public sharing anticipated next year.
Regulatory Pathways: Plans to initiate a registration-enabling study for breast cancer, with progression-free survival as a likely primary endpoint.
Partnership Opportunities: Exploring global and regional partnerships to enhance development and commercialization of pela.

4. Bad News, Challenges, or Points of Concern

Leadership Transition: The ongoing CEO search may create uncertainty regarding strategic direction during this transitional period.
Regulatory Engagement: While the FDA is aware of the pancreatic cancer program and granted fast-track designation, there have been no recent discussions, which may slow progress.
Market Competition: The evolving landscape in breast cancer treatment, particularly with the rise of antibody-drug conjugates, presents challenges for pela's positioning.

5. Notable Q&A Insights

Trial Design for Breast Cancer: Anticipated primary endpoint for the upcoming breast cancer study is progression-free survival, with discussions with the FDA ongoing.
Business Development Focus: Prioritizing partnerships for both global and regional rights, particularly in breast and pancreatic cancer.
Combination Therapies: There is ongoing exploration of combining pela with checkpoint inhibitors, particularly in pancreatic cancer, where synergy has been observed.

Overall, Oncolytics Biotech is making significant strides in clinical development and business strategy, but faces challenges related to leadership transition and market competition. The company remains optimistic about the potential of pelareorep across various cancer indications.

ONCY — Oncolytics Biotech Inc.